Antithrombin Heparin
Antithrombin Heparin - Related Videos
02:21
Purification of Viral Integrase Using Heparin Affinity Chromatography
0 Views •
2026
Source: Lopez Jr., M. et al. Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase. J. Vis. Exp. (2017)This video demonstrates the procedure for purifying viral integrase from bacterial nuclease contamination using heparin Sepharose column chromatography followed by SDS-PAGE analysis to confirm protein purity.
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
0 Views •
Cited by 2 •
2017
A construct encoding TMEM184A with a GFP tag at the carboxy-terminus designed for eukaryotic expression, was employed in assays designed to confirm the identification of TMEM184A as a heparin receptor in vascular cells.
12:27
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
0 Views •
Cited by 2 •
2016
Self-assembled polyelectrolyte complexes (PEC) fabricated from heparin and protamine were deposited on alginate beads to entrap and regulate the release of osteogenic growth factors. This delivery strategy enables a 20-fold reduction of BMP-2 dose in spinal fusion applications. This article illustrates the benefits and fabrication of PECs.
01:30
Anticoagulant Drugs: Low-Molecular-Weight Heparins
0 Views •
2024
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
03:40
Heparin Affinity Chromatography-Based Baculovirus Purification: A Technique to Isolate Baculovirus From Insect Cell Supernatant
0 Views •
2025
In this video, we demonstrate the technique to isolate baculovirus from an insect cell supernatant using heparin affinity chromatography. The isolation is facilitated by the affinity between the heparin in the column to the baculovirus envelope glycoprotein.
FAQs
Heparin binds to antithrombin and induces a conformational change in the protein. This altered structure greatly accelerates antithrombin’s ability to inactivate thrombin and factor Xa. The binding event therefore acts as an activating mechanism rather than merely adding another inhibitor to the coagulation system, making the interaction central to controlling clot formation.
Thrombin and factor Xa are key enzymes in the coagulation cascade, so their inactivation directly limits the enzymatic processes that promote clot formation. By accelerating antithrombin-mediated inhibition of both targets, heparin strengthens an endogenous anticoagulant pathway. This explains why the interaction has such a strong effect on regulating coagulation.
The important distinction is the change in reaction efficiency produced by heparin binding. Antithrombin is the plasma protein that limits clot formation, while heparin induces a conformational change that greatly accelerates its inactivation of thrombin and factor Xa. Thus, the interaction modifies the effectiveness of antithrombin rather than replacing its role.
The mechanism connects molecular regulation of coagulation with the development or prevention of thrombosis. If antithrombin activity is enhanced, thrombin and factor Xa are inactivated more rapidly, limiting clot formation. This relationship provides a framework for understanding how heparin-based anticoagulation controls coagulation and why altered antithrombin function can complicate interpretation.
Laboratory evaluation can be used to assess anticoagulant activity associated with the interaction. It can also support investigation of antithrombin deficiency and help interpret situations in which heparin resistance is suspected. These evaluations connect observed anticoagulant performance with the function of the antithrombin pathway, supporting analysis of abnormal or inadequate coagulation control.
Both unfractionated heparin and low-molecular-weight heparin are clinically relevant because their use depends on the anticoagulant interaction with antithrombin. The mechanism supports their application in preventing or treating thrombosis. In biology and biomedical research, recognizing this shared basis helps relate therapeutic heparin use to antithrombin-dependent control of coagulation.
The interaction provides a mechanistic basis for investigating strategies that control coagulation. Researchers can examine how antithrombin activity, heparin enhancement, thrombin inhibition, and factor Xa inhibition relate to anticoagulant outcomes. This framework is also useful when studying antithrombin deficiency or heparin resistance, because both conditions may alter how effectively coagulation is regulated.